Course Description

During this course Dr. Lewis Silverman will describe recent data relative to somatic mutations in patients with MDS and their implications for diagnosis and prognosis. He will explain the State of the Science for the use of hypomethylating agents (HMA), including best practice, and options for HMA failure. Dr. Silverman will also discuss novel targets and targeted agents in clinical trials showing promise in the treatment of MDS.

Target Audience

This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

• Describe recent data relative to somatic mutations in patients with MDS and their implications for diagnosis and prognosis.
• Explain the State of the Science for the use of hypomethylating agents (HMA), including best practice, and options for HMA failure.
• Discuss novel targets and targeted agents in clinical trials showing promise in the treatment of MDS.

Faculty

Lewis Silverman, MD

Director
Research Program for Studies in the Myelodysplastic Syndrome
Icahn School of Medicine at Mount Sinai
New York, NY
Dr. Silverman discloses no financial relationships with pharmaceutical or medical product manufacturers.